Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 92 peer-reviewed journal articles Updated
Infectious Disease

Alveolar Echinococcosis: A Patient Guide

At a Glance

Alveolar echinococcosis is a slow-growing parasitic disease that usually affects the liver. Complete surgical removal is the only potential cure when feasible; otherwise, long-term or lifelong albendazole suppresses the parasite, with monitoring for at least a decade.

Alveolar echinococcosis (AE) is a rare and complex condition caused by the larval stage of a tiny parasite called Echinococcus multilocularis. While it is an infection, it does not behave like a typical illness; instead, it acts like a slow-growing, infiltrative tumor that primarily takes root in the liver [1][2]. Humans are “aberrant hosts” for this parasite, meaning we are infected by accident—usually through the accidental ingestion of microscopic eggs after hand-to-mouth contact with contaminated soil, unwashed produce, or the fur of infected animals like foxes or dogs [3][4]. The disease is not contagious from person to person. After ingestion, the parasite can grow silently within the body for 5 to 15 years before any symptoms appear.

Because AE looks and behaves so much like liver cancer, the diagnostic journey can be a high-stress experience that requires specialized imaging and blood tests to untangle. Doctors use a combination of ultrasound, CT, and MRI scans to map the parasite’s “infiltrative” growth into liver tissue, bile ducts, and blood vessels [5][2]. To provide a clear anatomical roadmap for treatment, experts use the WHO-IWGE PNM staging system, which classifies the disease based on its extent in the liver (P), its spread to neighboring organs (N), and whether it has traveled to distant sites like the lungs or brain (M) [6][7].

The primary goal of treatment is the complete removal of the parasite through a radical resection, which is currently the only potential cure for the condition [8]. When a successful surgery is performed, patients typically take anti-parasitic medication for at least two years to ensure the parasite does not return [9]. However, because the parasite often grows near vital structures, surgery is not always possible. In these “unresectable” cases, the standard of care is long-term, and often lifelong, medication with benzimidazoles like albendazole [7][10]. These drugs are parasitostatic, meaning they do not necessarily kill the parasite but suppress it to prevent further damage [10].

Living with AE is a long-term commitment that requires a dedicated multidisciplinary care team, including liver surgeons, infectious disease specialists, and radiologists [11][12]. Because the parasite can remain dormant for a very long time, individualized regular monitoring with imaging and blood tests is required for at least a decade [13][14]. While the diagnosis can be overwhelming, modern medical management—through radical surgery when feasible and continuous therapy—has substantially improved outcomes, transforming AE into a chronic, controllable condition for many patients [7].

In this guide

6 chapters

01

Understanding Alveolar Echinococcosis

Learn how alveolar echinococcosis affects the liver, how people are exposed, and how it is treated, monitored, and managed as a chronic condition over time.

02

Biology, Symptoms, and the Diagnostic Pathway

Learn how alveolar echinococcosis develops, causes symptoms, and is diagnosed with ultrasound, CT, MRI, PET/CT, serology, and specialist-planned biopsy.

03

Staging Your Condition: The PNM System

Learn how PNM staging maps alveolar echinococcosis in the liver, nearby organs, and distant sites—and how imaging and anatomy guide treatment decisions.

04

Surgical and Interventional Strategies

Learn how surgery, liver transplantation, ex-vivo procedures, and interventional treatments are used for alveolar echinococcosis, including when the disease is unresectable.

05

Anti-Parasitic Medications (Benzimidazoles)

Learn how albendazole and mebendazole manage alveolar echinococcosis, including treatment duration, liver and blood monitoring, side effects, pregnancy safety.

06

Long-Term Monitoring and Emergencies

Learn how alveolar echinococcosis is monitored for at least 10 years, how PET/CT and Em18 tests are interpreted, and which symptoms require emergency care.

Common questions in this guide

How does someone get alveolar echinococcosis, and is it contagious?
Alveolar echinococcosis develops after a person accidentally swallows microscopic Echinococcus multilocularis eggs, often after hand-to-mouth contact with contaminated soil, unwashed produce, or the fur of infected foxes or dogs. It is not spread from person to person.
What tests are used to diagnose alveolar echinococcosis?
Doctors combine ultrasound, CT, MRI, and blood tests to identify the parasite’s infiltrative growth and distinguish alveolar echinococcosis from conditions such as liver cancer. Imaging also shows whether the disease involves liver tissue, bile ducts, blood vessels, or other organs.
What does the WHO-IWGE PNM stage tell me?
The PNM system describes how much of the liver is involved, whether nearby organs are affected, and whether the disease has reached distant organs such as the lungs or brain. The stage helps the medical team judge whether complete surgery is possible or long-term medication is needed.
Can alveolar echinococcosis be cured with surgery?
A radical resection that removes all parasite-infected tissue with clear margins is the only potential cure described for alveolar echinococcosis. When surgery is successful, anti-parasitic medication is usually continued for at least two years to reduce the risk of the parasite returning.
What treatment is used if alveolar echinococcosis cannot be removed?
When surgery is not possible, long-term and often lifelong treatment with benzimidazoles such as albendazole is standard. These medicines are parasitostatic, meaning they suppress the parasite and prevent further damage rather than reliably killing it.
How long will I need follow-up for alveolar echinococcosis?
Because the parasite can remain dormant for a very long time, individualized follow-up with imaging and blood tests is needed for at least 10 years. Your specialist team may tailor the schedule and tests, which can include PET/CT scans and antibody blood tests.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Has my case been reviewed by a multidisciplinary team at an expert reference center for alveolar echinococcosis?
  2. 2.What is my current WHO-IWGE PNM stage, and how does it determine whether my treatment is focused on a surgical cure or long-term medication?
  3. 3.If surgery is an option, can we achieve an R0 resection with clear margins while leaving enough healthy liver?
  4. 4.What is the plan for my long-term monitoring, including PET/CT scans and antibody blood tests, over the next decade?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Global Distribution of Alveolar and Cystic Echinococcosis.

    Deplazes P, Rinaldi L, Alvarez Rojas CA, et al.

    Advances in parasitology 2017; (95()):315-493 doi:10.1016/bs.apar.2016.11.001.

    PMID: 28131365
  2. 2

    Disseminated alveolar echinococcosis resembling metastatic malignancy: a case report.

    Caire Nail L, Rodríguez Reimundes E, Weibel Galluzzo C, et al.

    Journal of medical case reports 2017; (11(1)):113 doi:10.1186/s13256-017-1279-2.

    PMID: 28416007
  3. 3

    A systematic review and meta-analysis on anthelmintic control programs for Echinococcus multilocularis in wild and domestic carnivores.

    Umhang G, Possenti A, Colamesta V, et al.

    Food and waterborne parasitology 2019; (15()):e00042 doi:10.1016/j.fawpar.2019.e00042.

    PMID: 32095614
  4. 4

    The Echinococcoses: Diagnosis, Clinical Management and Burden of Disease.

    Kern P, Menezes da Silva A, Akhan O, et al.

    Advances in parasitology 2017; (96()):259-369 doi:10.1016/bs.apar.2016.09.006.

    PMID: 28212790
  5. 5

    Proposal of a computed tomography classification for hepatic alveolar echinococcosis.

    Graeter T, Kratzer W, Oeztuerk S, et al.

    World journal of gastroenterology 2016; (22(13)):3621-31 doi:10.3748/wjg.v22.i13.3621.

    PMID: 27053854
  6. 6

    Programmed death-ligand1 is a determinant of recurrence in alveolar echinococcosis.

    Joliat GR, Martins-Filho SN, Haefliger S, et al.

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2023; (129()):285-288 doi:10.1016/j.ijid.2023.01.043.

    PMID: 36775187
  7. 7

    Comparison of local ablation with Albendazole or laparoscopic hepatectomy combined with Albendazole in the treatment of early hepatic alveolar echinococcosis.

    A J, Chai J, Shao Z, et al.

    Frontiers in public health 2022; (10()):960635 doi:10.3389/fpubh.2022.960635.

    PMID: 36276387
  8. 8

    Comment on surgical approaches for definitive treatment of hepatic alveolar echinococcosis: results of a survey in 178 patients.

    Akbulut S, Sahin TT

    Parasitology 2020; (147(13)):1408-1410 doi:10.1017/S0031182020001390.

    PMID: 32741385
  9. 9

    Current interventional strategy for the treatment of hepatic alveolar echinococcosis.

    Vuitton DA, Azizi A, Richou C, et al.

    Expert review of anti-infective therapy 2016; (14(12)):1179-1194 doi:10.1080/14787210.2016.1240030.

    PMID: 27686694
  10. 10

    Chemotherapy for the treatment of alveolar echinococcosis: Where are we?

    Autier B, Robert-Gangneux F, Dion S

    Parasite (Paris, France) 2024; (31()):56 doi:10.1051/parasite/2024055.

    PMID: 39311470
  11. 11

    Alveolar Echinococcosis of the Liver with a Rare Infiltration of the Adrenal Gland.

    Šimeková K, Rosoľanka R, Szilágyová M, et al.

    Helminthologia 2021; (58(1)):100-105 doi:10.2478/helm-2021-0002.

    PMID: 33664623
  12. 12

    Hepatobiliary alveolar echinococcosis treated with delayed resection following percutaneous drainage.

    Quan S, Sander I, Waldner D, et al.

    Annals of hepato-biliary-pancreatic surgery 2025; (29(4)):504-509 doi:10.14701/ahbps.25-124.

    PMID: 41120191
  13. 13

    Late vertebral and pulmonary alveolar echinococcosis after hepatic surgery mimicking spinal and disseminated tuberculosis: a case report.

    Li C, Luo F, Wang X

    Tropical medicine and health 2026; (54(1)).

    PMID: 42629577
  14. 14

    Fast-Growing Alveolar Echinococcosis Following Lung Transplantation.

    Dupont C, Grenouillet F, Mabrut JY, et al.

    Pathogens (Basel, Switzerland) 2020; (9(9)) doi:10.3390/pathogens9090756.

    PMID: 32948027

This page is for informational purposes only and does not constitute medical advice. An expert infectious disease or liver team should interpret your scans, stage, and treatment plan.

Get notified when new evidence is published on Alveolar echinococcosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.